Industry Ignited Podcast
Industry Ignited is a platform for bold conversations with leaders who are transforming the way business gets done. Each episode spotlights breakthrough stories from the industrial, manufacturing, biotech, chemical, and B2B sectors, giving you an inside look at how top executives, innovators, and changemakers tackle real-world challenges and drive meaningful growth.
Hosted by Dr. Leeanne Aguilar—entrepreneur, executive coach, and marketing strategist—Industry Ignited goes beyond surface-level discussions to uncover the strategies, mindsets, and lessons that fuel leadership at the highest level. From navigating complex operations and scaling companies to rethinking culture and preparing for the future of work, every conversation is designed to inspire, challenge, and equip you with fresh perspectives.
Whether you’re an executive, entrepreneur, or emerging leader, this podcast will spark ideas, expand your vision, and ignite the drive to lead with confidence in today’s evolving business landscape.
Industry Ignited Podcast
The Science of Saving Vision: David Esposito, CEO of ONL Therapeutics | Ep. 48
In this episode of Industry Ignited, Dr. Leeanne Aguilar speaks with David Esposito, Chief Executive Officer of ONL Therapeutics, a decorated combat veteran and seasoned healthcare executive who has successfully built and scaled multiple life science companies. David shares how leadership forged on the battlefield now guides his work at the forefront of biotech innovation, where ONL Therapeutics is pioneering a first-in-class approach to preserving vision by preventing Fas-mediated retinal cell death—the root cause of many blinding conditions. He discusses the realities of leading high-risk clinical-stage companies, the discipline required to navigate long clinical trials, and the importance of humility, communication, and purpose when outcomes directly impact patients’ quality of life. Through ONL’s breakthrough therapeutic candidate, ONL1204, David illustrates how courage, compassion, and scientific rigor must work together to advance medicine, move science forward, and give patients a real chance to preserve their sight.